State of New Jersey Common Pension Fund D purchased a new position in shares of Uniqure NV (NASDAQ:QURE) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 32,700 shares of the biotechnology company’s stock, valued at approximately $1,287,000. State of New Jersey Common Pension Fund D owned approximately 0.09% of Uniqure as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently added to or reduced their stakes in QURE. Sanders Morris Harris LLC acquired a new position in shares of Uniqure in the 2nd quarter valued at approximately $3,084,000. First Citizens Bank & Trust Co. acquired a new position in shares of Uniqure in the 2nd quarter valued at approximately $211,000. Xact Kapitalforvaltning AB acquired a new position in shares of Uniqure in the 2nd quarter valued at approximately $328,000. Henry James International Management Inc. raised its position in shares of Uniqure by 16.6% in the 2nd quarter. Henry James International Management Inc. now owns 105,844 shares of the biotechnology company’s stock valued at $8,272,000 after purchasing an additional 15,058 shares in the last quarter. Finally, Eqis Capital Management Inc. raised its position in shares of Uniqure by 14.2% in the 2nd quarter. Eqis Capital Management Inc. now owns 27,126 shares of the biotechnology company’s stock valued at $2,120,000 after purchasing an additional 3,379 shares in the last quarter. 62.81% of the stock is currently owned by hedge funds and other institutional investors.
In other news, CEO Matthew C. Kapusta sold 8,000 shares of the stock in a transaction on Wednesday, October 23rd. The stock was sold at an average price of $43.22, for a total value of $345,760.00. Following the completion of the transaction, the chief executive officer now owns 378,836 shares of the company’s stock, valued at $16,373,291.92. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Alexander Edward Kuta III sold 4,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $47.26, for a total value of $189,040.00. Following the completion of the transaction, the vice president now directly owns 30,578 shares of the company’s stock, valued at approximately $1,445,116.28. The disclosure for this sale can be found here. In the last three months, insiders sold 36,769 shares of company stock valued at $1,759,426. Company insiders own 2.91% of the company’s stock.
QURE traded up $0.49 during trading on Tuesday, reaching $54.23. 2,911 shares of the company were exchanged, compared to its average volume of 474,720. The stock has a market cap of $2.34 billion, a P/E ratio of -23.11 and a beta of 0.84. The firm has a 50 day moving average of $45.27 and a 200 day moving average of $58.08. The company has a current ratio of 14.33, a quick ratio of 14.33 and a debt-to-equity ratio of 0.19. Uniqure NV has a 52 week low of $21.98 and a 52 week high of $82.49.
Uniqure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, October 28th. The biotechnology company reported ($0.58) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.23. Uniqure had a negative return on equity of 51.12% and a negative net margin of 1,670.86%. The firm had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.24 million. As a group, analysts forecast that Uniqure NV will post -3 earnings per share for the current fiscal year.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Recommended Story: What is a Lock-Up Period?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.